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Knowledge and reasoning adaptationThis work introduces HaemoKBS, a novel Haemovigilance decision support system for adverse reactions
in blood recipients. Machine learning inference and rule-based reasoning were applied to build the
underlying decision support models, namely to automatically extract evidence from different types of
data included in hospital notifications and incorporate a priori expert knowledge. The ultimate aim is
to dynamically learn and improve the reasoning abilities of the system and thus, be able to provide edu-
cated recommendations to hospital notifiers along with understandable explanations on the acquired
knowledge. Experiments over the records of the Portuguese National Haemovigilance System from the
last 10 years demonstrate the practical usefulness of HaemoKBS, which will contribute to a better depic-
tion of the adverse reactions and to flag any incomplete notification enforcing data quality.
 2020 Elsevier B.V. All rights reserved.1. Introduction and motivation
The use of blood as a therapeutic agent has always been an
essential medical therapy, namely for several pathologies, acci-
dents, and surgical procedures. However, such therapy often
entails risks [1]. Although the major causes of transfusion-related
morbidities, such as blood group incompatibility and transmission
of infectious agents, are now significantly reduced, real-time and
continuous monitoring is still required for this and other possible
adverse reactions [2].
In 1994, the French Blood Agency started setting a network of
healthcare professionals with specific roles to signal, notify and
review transfusion-related adverse reactions [3]. This monitoring
system became the first national Haemovigilance system world-
wide. Since then, most of the developed countries have imple-
mented and legislated Haemovigilance programs [4]. The aims
are mainly two-fold: (i) to monitor the quality and safety of bloodcomponents throughout the supply-value transfusion chain of
national healthcare facilities (i.e. from donor to recipient); and,
(ii) to trigger appropriate and timely actions when there is a poten-
tial threat to the safety of transfusion.
Existing Haemovigilance systems are usually implemented at
the national level. Thus, the number of institutions handling blood
transfusions, the number of hospital notifiers (i.e. trained health-
care staff) responsible for notifying about the occurrence of
adverse reactions, and the number of annual notifications may
vary considerably from country to country [5]. Likewise, the sup-
porting software is quite diverse in nature and degree of automa-
tion. Nevertheless, national Haemovigilance organisations are
bound to similar laws. For example, current European Union legis-
lation explicitly specifies the level of detail that the Haemovigi-
lance systems of member states should ensure [6].
Aside from legal policies, well-known international medical
institutions are invested in the standardisation of this information
and its supporting tools [7]. The International Society of Blood
Transfusion has a working party on Haemovigilance [8] and the
Centers for Disease Control and Prevention released a set of stan-
dards for the classification of transfusion reactions [9].
Since the general protocol of notification of adverse reactions in
patients transfused with blood products can be considered fairly
A. Ramoa et al. / Neurocomputing 423 (2021) 756–767 757established for most adverse reactions, computational processing
is welcomed to some extent, notably the introduction of intelligent
methods of validation that enforce data quality. Therefore, the pre-
sent work proposes a novel knowledge-based system, named Hae-
moKBS, which supports the work of notifiers and Haemovigilance
experts throughout the process of notifying and curating adverse
reactions in blood recipients. The system integrates both expert
knowledge and machine learning inference in order to validate
and act upon notifications adequately. The main contribution lays
on augmenting the discriminatory power of categorisation by con-
tinuously learning from previous experience (i.e. validated notifi-
cations) as well as prior knowledge (i.e. expert know-how). The
rationale is that, by combining the automatic categorisation of
adverse reactions with well-established knowledge, the manual
effort required from national experts may be reduced while enforc-
ing data quality in a sustainable, educated and continuous way.
The Portuguese Haemovigilance System, which is fully compli-
ant with EU laws and international Haemovigilance guidelines, is
used as a case study. Since 2007, this system receives adverse reac-
tion notifications via a restricted access web application. From
2008 to 2017, the system registered, on average, 427 adverse reac-
tions per year [10,11]. Currently, all notifications are manually
reviewed by a panel of national Haemovigilance experts that vali-
date the coherence of the designated adverse reaction based on the
reported medical observations.
The remainder of the paper is organised into the following sec-
tions. Section 2 presents an overview of decision-making systems
applied to domains with similar characteristics. Section 3 intro-
duces the general architecture of the proposed system, namely
its internal knowledge base and curation workflow. Section 4
demonstrates the validity and potential of the developed system
using the notifications collected in the Portuguese National Hae-
movigilance system. Section 5 states the conclusions drawn from
the implementation of HaemoKBS as well as depicts future
developments.2. Related work
Over the past three decades, decision support systems have
been successfully established in numerous domains. There is a
variety of system types, all of which have the ultimate goal of
assisting humans to make appropriate decisions for practical
(and often challenging) problems. Among these, expert systems
and recommender systems follow the knowledge-driven approach,
i.e. take into account various aspects of the domain and integrate
different types of knowledge within reasoning to tackle the prob-
lem with appropriate actions [12].
Medical decision support systems were introduced as an inno-
vative and valuable way for providing clinicians and patients with
varied clinical knowledge and enhancement of the overall quality
of care [13,14]. In this regard, several studies have argued the case
for implementing systems that are able to provide motivated sug-
gestions [15] as well as encode clinical practice guidelines (i.e.
emulate the process followed by experts to take decisions) [16].
Diagnosis prediction and treatment learning and recommendation
are long-term lines of research, including challenges in the combi-
nation of static and longitudinal data features and the added value
of the application of machine learning methods [17]. Nonetheless,
considerable attention is also paid to the design of surveillance and
reporting systems that rapidly detect and take appropriate action
to adverse and undesirable events. Spontaneous reporting has been
the main source to detect such events for years, but data quality
issues, such as the over-reporting of highly common events, miss-
ing and incomplete data, duplicated reporting, voluntary submis-
sion, and the high cost of human expert’s assessment, raise theneed for automated and intelligent mechanisms of notification
and validation.
Pharmacovigilance, i.e. the detection and continuous monitor-
ing of adverse drug reactions or other drug-related problems, is
actively engaged in implementing surveillance knowledge-based
systems [18]. Databases, such as the Adverse Event Reporting Sys-
tem of the Food and Drug Administration, contain reports on
adverse events that have been spontaneously communicated by
clinical staff and consumers. Nevertheless, the success of surveil-
lance systems lies in the quality of the submitted reports and man-
ual expert validation [19,20]. Usually, evaluators try to find
additional, similar cases in the system, in other databases or in
the medical literature and search for any common trend, causal
relationship, or pattern of events to identify potential risk factors
or any other specificities. One of the main challenges in determin-
ing the causality of such events is that there is no gold standard
(i.e. ground truth) to compare the relative performance of compu-
tational algorithms and expert’s assessment. Therefore, increasing
attention is paid to the application of retrospective data (including
administrative claims, electronic health records, laboratory test
results, radiology test results, and other alike) as well as to the
encoding of standardised assessments and any regulations (often
expressed as a set of specific ‘yes/no’ questions regarding event
features) typically used by human experts (and many times, gener-
ated by previous experience). A recent review pinpointed the
specificities and challenges of decision support in Pharmacovigi-
lance, including the methods and frameworks used for processing
such data, and the machine learning algorithms developed for the
detection of adverse drug reactions [21].
To the best of the authors’ knowledge, there is no previous
attempt to introduce automated decision making in Haemovigi-
lance systems. Current systems rely solely on manual expert cura-
tion to guarantee the timely and accurate characterisation of
adverse reactions in blood recipients and blood donors [5]. So, in
this domain, data quality is still heavily dependent on the prompt
and comprehensive notification of the potential reaction as well as
the experience of the curators in assessing cases that do not fully
comply with the common, standardised description of the
reactions.
Decision support can be introduced in Haemovigilance systems
in various, combinable ways with the ultimate objectives of
enhancing data quality, reducing costs with expert curation, and
enforcing efficient monitoring. Most notably, lessons can be
learned from developments in similar (purpose and concern-
related) domains, such as Pharmacovigilance, as well as from other
health expert systems that aim to emulate the behaviour of human
experts, facilitate human collaboration, and capture implicit
domain knowledge for educated decision-making.
The so-called hybrid decision support systems that combine
expert-defined static rules with supervised learning are well-
established in medical domains. In particular, the number of med-
ical applications of case-based reasoning systems has increased
considerably over the last decade [22–24]. Generally speaking, a
case can be defined as a set of meaningful domain features coupled
with information about the applied ‘‘solution”, i.e. a situation-
action domain-specific pattern [25]. The success of the methodol-
ogy lies in three main capabilities, namely: the ability to produce
a rich and evolvable representation of both implicit (i.e. previous
cases) and explicit knowledge (i.e. human expertise); the ability
to implement efficient and flexible ways to retrieve existing data;
and, the ability to apply analogical reasoning to solve new situa-
tions [25]. This is well-described in the review of Begum and col-
leagues, which summarises 34 case-based reasoning medical
systems, in terms of purpose-oriented properties and construction
characteristics [26]. Also interesting, another review explored
intrinsic weaknesses affecting the application of this methodology
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ence of competence gaps affecting case base contents, challenges
in the definition of a suitable adaptation strategy, and other com-
plementary issues related to the increasing complexity of the
domain [27].
On top of all these developments, it is also worth mentioning
the development of rule-based systems that model clinical knowl-
edge using sets of rules, in the form of IF-THEN statements [28].
That is, based on the available cases, the system selects one rule
from the knowledge base to be fired in order to generate new
knowledge or execute the corresponding actions. Forward chaining
is the most extended reasoning mechanism for clinical prognosis,
monitoring and control rule-based applications, i.e. checking the
left-hand side of the rules against the available cases and launching
the right-hand side of the rule meeting the conditions. Likewise,
and regardless of the architecture of the implemented systems,
the potential of machine learning methodologies has been widely
tested for improving disease detection, clinical decision support,
and workflow efficiencies [29]. Finally, various methodologies have
been proposed to extract and acquire medical knowledge, includ-
ing the use of theoretical models to interchange knowledge
between rules [30,31].3. HaemoKBS: application architecture and operational process
The main aim of HaemoKBS is to help in the automatic classifi-
cation and validation of the notified adverse reactions based on the
provided observations and prior expert knowledge. As illustrated
in Fig. 1, the hospital notifier reports a collection of medical obser-
vations that are used by the hybrid classification model to produce
a prioritised list of possible reactions. The higher is the number of
similar symptoms and signs, combined with different ponderations
for specific reactions, the higher is the probability of the reaction
type (as an example, in a hypotensive reaction, low blood pressure
should be overvalued if it appears as a single symptom and under-
valued if accompanied by other symptoms). After the notifier
makes a decision (which may not necessarily lie on the reactionFig. 1. General architecture of the knowledge-based decision support system propwith top probability), the reported case is matched against the
decision tree corresponding to the selected reaction type. If it com-
plies with expert knowledge, the notification is considered valid
and saved in the knowledge base. Otherwise, the system will alert
the hospital notifier of the discrepancies so that the notification
can be amended or submitted as-is. Whenever a notification is sub-
mitted without conformity with prior knowledge, it is sent to the
Haemovigilance expert for manual validation. The Haemovigilance
expert may accept or reject the proposed classification, with the
added possibility of postponing the decision until additional evi-
dence becomes available (e.g. after asking the hospital notifier
for further details); when the notification is finally validated, it is
stored in the knowledge base for future reuse, namely to retrain
and apply the predictive model. The national expert decides
whether retraining is necessary, and may then provide additional,
useful information for the update process.3.1. Knowledge storage and notification definition
The knowledge base of the HaemoKBS system keeps all the val-
idated notifications. Each notification stored in this database has a
unique identifier and is defined by the information features
described in Table 1. Apart from the timestamps of the notification
and the occurrence of the adverse reaction, the notifier specifies
the age and gender of the patient and characterises the reaction
in terms of imputability and severity of the reaction, i.e. the
strength of the association between the transfusion and the occur-
rence of adverse reaction and the severity of the episode, as well as
signs, symptoms and exam results.
The Adverse Transfusion Reaction (ATR) (e.g. anaphylaxis, bac-
terial infection, acute haemolytic reaction, or hypotensive transfu-
sion reaction, coded numerically for simplicity) is described by the
feature tuple fI; S;G;A; SG; SM;M;Og as follows: I indicates how
strong is considered the association between the transfusion and
the adverse reaction (possible values are ‘‘evaluation not possible”,
‘‘excluded”, ‘‘possible”, ‘‘probable” and ‘‘definite”); S specifies the
degree of severity of the adverse reaction (possible values includeosed for the notification of adverse transfusion reactions (ATR) in recipients.
Table 1
Features included in an adverse reaction notification and used by HaemoKBS.
Attribute Type Description
Reaction code (RC) Nominal Identification of adverse reaction type
Imputability (I) Nominal Strength of the association between the transfusion and the adverse
reaction. Possible values: evaluation not possible, excluded, possible,
probable and definite
Severity (S) Ordinal Degree of the severity of the adverse reaction. Possible values: non-severe,
severe, life-threatening, death
Reaction type (ATR) Nominal An adverse reaction can occur from during the transfusion to months later.
Possible values: acute and delayed
Gender (G) Nominal Gender of the patient
Age (A) Nominal Age (in years) of the patient in the moment of transfusion was discretised
into 3 data bins (i.e. 0 < age < 18, 18  age < 65, and  65).
Signs (SG)
Anguish/Anxiety; Arrhythmia; Bradycardia; Bronchospasm/Sibilant; Cough;
Cyanosis; Dark urine; Disorientation; Dyspnoea; Epistaxis; Erythema/
Generalized Redness; Erythema/Localized Redness; Fever/Temperature rise;
Generalized Oedema; Haemorrhage; Hypertension; Hypotension;
Hypothermia; Jaundice; Localized Angioedema; Localized Oedema;
Maculopapular rash/Urticaria; Oligoanuria; Paleness; Psychomotor
agitation; Quincke’s Oedema; Skin Rash; Sweating/Diaphoresis; Syncope/
Loss of consciousness; Tachycardia; Tachypnoea/Polypnea/Hyperpnoea;
Tonic-clonic seizure; Urticaria; Vomiting
Boolean Medical signs observed in the patient by the healthcare staff.
Possible values: present and absent
Symptoms (SM)
Abdominal pain; Arthralgia; Diarrhoea; Headaches; Low back pain; Nausea;
Orthopnoea; Pain/Burning in the venous access; Shivers/Tremors; Thoracic
Pain; Vertigo/Dizziness
Boolean Symptoms mentioned by the patient to the healthcare staff.
Possible values: present and absent
Medications (M)
Adrenaline; Anti-histamines/steroids; Antipyretics; Bronchodilators;
Diuretics; Fluid Therapy; Hypotensors; Metoclopramide; Oxygen therapy
Boolean Medications administered to the patient.
Possible values: present and absent
Others (O)
Acute lung oedema; Cardiac arrest; Cardiac insufficiency; Decreased O2 sat;
Evidence of Positive Fluid Balance; Other unlisted findings; Shock; Viral
Infection, Absent before transfusion
Boolean Diagnostic test results and other characteristics that help in the diagnosis
and identification of the adverse reactions.
Possible values: present and absent
/ indicates alternative feature naming conventions.
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sents the gender of the transfusion recipient (i.e. ‘‘female” and
‘‘male”); A indicates the age of the transfusion recipient (i.e. age
in years of the recipient in the moment of transfusion, which
was later discretized into 3 bins); SG ¼ fSG1; SG2;    ; SG34g is the
set of observed signs (e.g. bradycardia, cyanosis or epistaxis, repre-
sented as Boolean variables); SM ¼ fSM1; SM2;    ; SM11g is the set
of manifested symptoms (e.g. headaches, nausea or vertigo, all rep-
resented as Boolean variables); M ¼ fM1;M2;    ;M9g is the set of
medications ministered to the patient (e.g. antipyretics, diuretics
or hypotensors, all represented as Boolean variables); and,
O ¼ fO1;O2;    ;O7g collects other possible manifestations of the
adverse reaction (e.g. acute lung oedema or decreased oxygen sat-
uration, all represented as Boolean variables).
3.2. Expert knowledge representation and inference on prior
notifications
The Portuguese Blood and Transplantation Institute has pub-
lished standardised descriptions, namely signs, symptoms and
other features, of the most common adverse reactions in their
blood recipients [32]. Such knowledge is represented as rules
stored in the knowledge base and a rule-based engine imple-
mented in-house enables the execution of these rule sets inside
the system. Each adverse reaction type is represented by a decision
tree, from which a WHEN–THEN rule set is easily derived by defin-
ing a new rule for each path from the root to a leaf node. Following
this strategy, the leaf node contains the decision part of the rule
whereas the path from the root to the leaf node determines its con-
ditions (i.e. the corresponding collection of signs, symptoms and
other possible features). As illustrative examples, Figs. 2 and 3 pre-
sent the decision trees established for respiratory reactions andhaemolytic reactions. In particular, Fig. 2 describes respiratory
reactions as reactions happening hours after the transfusion and,
most specifically, states that transfusion-associated circulatory
overload (TACO) and transfusion-related acute lung injury (TRALI)
happen within the first 6 h whereas transfusion-associated dysp-
noea (TAD) occurs between the 6 to 24 h after. Differentiation
between TACO and TRALI reactions depends on the predominance
of other medical observations (e.g. presence of pulmonary oedema
or oxygen saturation below 90%). Likewise, Fig. 3 divides haemoly-
tic reactions into those occurring within the first 24 h and delayed
reactions. Then, clinical tests (e.g. DAT test) and the observation of
physical causes of haemolysis are determinant to establish
whether the reaction is immune or not.
As depicted in Fig. 1, the hospital notifier is free to accept the
reaction code recommendation provided by the predictive model
of HaemoKBS (typically the one with the highest score) or make
another decision. Regardless, the notification will be always vali-
dated against the expert knowledge, i.e. notification data will be
matched against the decision tree built by human experts for that
adverse reaction type.
Consistent notifications will be automatically validated and
inserted in the knowledge base. In case of discrepancy, the failed
decision rule helps to explain which observations are missing or
are inconsistent with that reaction type. The hospital notifier is
given then the opportunity to make two possible amendments:
(i) to update the set of observations described in the notification
(i.e. rectify any of the values), and/or (ii) to choose another reac-
tion. If no amendment is made, the inconsistent notification will
be sent to the Haemovigilance expert for manual curation.
Validated notifications are inserted in the knowledge base and
are applied to re-train the predictive models whenever the
national expert considers it appropriate.
Fig. 2. Manually defined decision tree used by experts to classify respiratory reactions, i.e. transfusion-associated dyspnoea (TAD), transfusion-associated circulatory
overload (TACO) and transfusion-related acute lung injury (TRALI).
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In this section, the predictive performance of the models pro-
posed for the classification of adverse reactions in blood recipients
is evaluated. Both the experimental protocol and the results are
presented and discussed.
4.1. Experimental setup
The records of the Portuguese National Haemovigilance System
supported the training and testing of the predictive models. These
records are not published individually, as they contain sensitive
information, nevertheless they are compiled by the Portuguese
Haemovigilance System and a descriptive report is published
annually [10].
The primary goal was to predict the most probable types of
adverse reactions based on the observations supplied by the hospi-
tal notifiers.
Experiments considered notifications from the last 10 years of
activity, which have been manually curated by experts. Fig. 4
shows the distribution of these notifications per type of adverse
reaction throughout the years. This dataset contains a total of
3.829 notifications distributed as follows: the febrile non haemoly-
tic transfusion reactions (i.e. ATR code 15) account for 49% of thenotifications, followed by the acute allergic reactions (i.e. ATR code
16), which represent 26% of the notifications; each of the other of
adverse reactions represents less than 10% of the dataset. Most
notably, notifications of transfusion-related acute lung injuries
(i.e. TRALI, with ATR code 9), viral infections (i.e. ATR code 10), bac-
terial infections (i.e. ATR code 7) and delayed haemolytic transfu-
sion reaction (i.e. ATR code 14) are almost inexistent (below 1%).
This dataset was divided into a training set (2.873 examples)
and a test set (956 examples). Initially, experiments focused on
validating the performance of predictive models trained to recog-
nise all possible adverse reaction types (i.e. the implementation
of the discriminative model), however, these predictive models
achieved poor performance. As such, the training set was further
divided into three subsets, namely a subset containing only the
notifications of the most frequent reactions (i.e. haemolytic trans-
fusion reactions and acute allergic reactions), another one keeping
the seldom occurring reactions (i.e. TRALI, viral and bacterial infec-
tions and delayed haemolytic transfusion reactions), and a third
one containing the rest of the notifications (i.e. those concerning
ordinarily occurring reactions).
While the unbalanced distribution of adverse reaction types
challenged the machine learning processes, sampling techniques
(or similar) were not considered because, in countries with High
Development Index [33] (such as the present case), Haemovigi-
Fig. 3. Manually defined decision tree used by experts to classify haemolytic reactions, i.e. delayed haemolytic transfusion reaction, acute haemolytic immune transfusion
reaction and acute haemolytic non-immune transfusion reaction.
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adverse reactions is expected to be low and, in particular, adverse
reactions such as TRALI have become highly unlikely to occur.
Therefore, the proposed classification model was devised as a
hybrid decision-maker that handled the whole spectrum of possi-
ble adverse reactions while providing specialised outputs for the
three subsets of reactions. Most notably, and as represented in
Fig. 5, the constructed hybrid classification model includes a dis-
criminative model that predicts the most probable ATR category
for the notified data, plus three models specialised in the predic-
tion of the specific ATR code: prevalent reactions (ATR codes 15
and 16), ordinary reactions (ATR codes 1, 17, 8, 18, 23 and 3) and
rare reactions (ATR codes 9, 10, 7 and 14).
All experiments conducted 10 fold cross-validation over the
training set and used the test set to perform a final validation over
previously unseen examples [34]. Exception made for the rare
reaction types (covering less than 2% of the dataset), for which
experiments carried out leave-on-out validation. The classification
models were developed with classic predictive algorithms, includ-
ing decision trees (DT) [35,36], Naïve Bayes (NB) [37], k-nearest
neighbours (k-NN) [37], support vector machines (SVM) [38,39],
random forest (RF) [40], adaptive boosting algorithms (AdaBoost)
[41–43], artificial neural networks (ANN) [44] and 5 Nearest
Neighbours (5NN) [45]. A grid search was applied to perform
hyperparameter optimisation, i.e. parameter combinations were
explored and the parameters that resulted in the best models were
chosen [46,47].
The micro-averaged values of Cohen’s kappa coefficient (Eq.
(1)), accuracy (Eq. (2)), error rate (Eq. (3)), precision (Eq. (4)), recall
(Eq. (5)), specificity (Eq. (6)), and F-score (Eq. (7)) were used as
evaluation metrics [48].k  p0  pe
1 pe
¼ 1 1 p0
1 pe
; ð1Þ
Accuracy ¼ number of true positives and true negatives
total of predictions
ð2Þ
Error rate ¼ number of false positives and false negatives
total of predictions
ð3Þ
Precision ¼ number of true positives
number of predicted positives
ð4Þ
Recall ¼ number of true positives
number of actual positives
ð5Þ
Specificity ¼ number of true negatives
number of actual negatives
ð6Þ
F-score ¼ 2 precision  recall
precisionþ recall ð7Þ
Experiments were conducted using the RapidMiner implemen-
tations of the aforementioned machine learning algorithms [49].
4.2. Results of model building
Tables 2–5 summarise the evaluation results for the machine
learning models, i.e. a total of 28 classification models were consid-
ered for the prediction of adverse reactions in blood recipient
based on 7 machine learning methods and 4 training sets.
Fig. 4. Distribution of the adverse reaction notifications recorded by the Portuguese National Haemovigilance System in the last decade.
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possible adverse reaction types presented poor performance
(Table 2). Notably, models showed poor ability to predict bacterial
infections (ATR code 7), TRALI (ATR code 9), and delayed haemoly-
tic transfusion reactions (14). Febrile non-haemolytic transfusion
reactions (ATR code 15) and acute allergic reactions (ATR code
16), i.e. the most commonly notified reactions, obtained the best
results, i.e. precision around or above 0.9 and recall, most of the
times, well above 0.9. Models showed modest values of perfor-
mance for TACO (ATR code 8), TAD (ATR code 17) and other acute
reactions (ATR code 1), i.e. most precision and recall values below
0.6. Overall, the top-performing models were RF (a grid search sup-
ported hyperparameter optimization considering combinations of
the number of estimators 2 [50, 100, 150, 200, 250, 300, 500], max-
imum depth 2 [20,25,30,35,40], and minimum samples in a leaf 2
[1, 10, 20, 50, 100], and the best parameters were number of esti-
mators = 200, maximum depth = 35, and minimum samples in a
leaf = 1) and SVM (a grid search supported hyperparameter opti-
mization combining values of C 2 [0.001, 0.01, 0.1, 1, 10, 100]
and values of gamma 2 [0.001, 0.01, 0.1, 1] and the best parameters
were C = 10 and gamma = 0.01) with a kappa metric of 0.75 and a
classification rate of 16% and 17%, respectively. The most notice-
able difference between these two models was the predictive abil-
ity to classify acute allergic reactions (ATR code 16), which are thesecond most common reactions. Considering the poor performance
of the RF model for this case (i.e. recall of 38%), the SVMmodel was
chosen as the discriminative component of the hybridised classifi-
cation model. Notably, this model is used to determine which
category-specific classification model should be applied to produce
the final prediction, i.e. the prevalent type classifier, the ordinary
type classifier, or the rare type classifier.
These results also offered relevant insights into the differentia-
tion of similar reactions based on notification data. For example,
false negatives on respiratory reactions were deemed two-fold,
i.e. TAD with ATR code 17 and TACO with ATR code 8, are often
due to misclassifications among themselves, whereas TRALI (ATR
code 9) was confused with acute haemolytic transfusion reaction
(ATR code 23) or other acute reaction (ATR code 1). The character-
isation of respiratory reactions is still looking for a final consensus
among experts. Working groups are addressing this characterisa-
tion, specially TRALI and TACO reactions [50–53], and therefore,
to an extent, it was somewhat expected and justifiable misclassifi-
cations between them. The confusion with acute haemolytic trans-
fusion reactions will be addressed in future developments with the
harmonization of the diagnostic test results and other characteris-
tics, namely by implementing a rule that strictly forbids a given
classification when a specific relevant test result (i.e. a positive
result in the direct antiglobulin test) is not available.
Table 2
Performance of the global predictive models covering all ATR types by 10-fold cross-validation.
ATR code
Kappa % accuracy 15 16 1 17 8 18 23 3 9 10 7 14
DT 0.71 80.61 0.9025 0.9168 0.493 0.5041 0.4894 0.5882 0.64 0.2069 0 1 0 0 Precision/Recall
0.9339 0.8644 0.5423 0.7176 0.2072 0.5128 0.3902 0.1935 0 0.8 0 0
NB 0.75 83.08 0.9255 0.8895 0.5689 0.5297 0.5481 0.7662 0.7297 0.3438 0.1429 0.6667 0 0
0.936 0.8989 0.4923 0.6294 0.5135 0.7564 0.6585 0.3548 0.1111 0.8 0 0
SVM 0.75 83.15 0.9062 0.8971 0.6818 0.552 0.7119 0.7195 0.7368 0.8 0 1 0 0
0.941 0.9043 0.4038 0.7176 0.3784 0.7564 0.3415 0.129 0 0.8 0 0
RF 0.75 83.78 0.8771 0.7119 0.6818 0.552 0.7195 0.8971 0.8 0.7368 0 0 0 1
0.9794 0.3784 0.4038 0.7176 0.7564 0.9043 0.129 0.3415 0 0 0 0.8
AB 0.73 82.6 0.8824 0.8768 0.5907 0.569 0.567 0.7258 0.619 0.75 0 1 0 0
0.9652 0.9082 0.4385 0.5824 0.4955 0.5769 0.3171 0.0968 0 0.6 0 0
ANN 0.74 82.84 0.9188 0.9092 0.5375 0.5102 0.5755 0.6974 0.7059 0.2632 0 0.5 0.2 0
0.9488 0.8923 0.4962 0.5882 0.5495 0.6795 0.5854 0.1613 0 0.2 0.2 0
5NN 0.72 81.73 0.8537 0.892 0.5515 0.5439 0.6 0.7302 0.8333 1 0 1 0 0
0.9787 0.9003 0.35 0.5471 0.4865 0.5897 0.122 0.0323 0 0.8 0 0
Fig. 5. Hybrid classification model architecture (in the upper right corner, the hybrid classification model showed in Fig. 1, acting as a visual aid to zoom in on the general
architecture of HaemoKBS).
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i.e. febrile non-haemolytic transfusion reactions (ATR code 15)
and acute allergic reactions (ATR code 16), obtained very good
results, i.e. a kappa over 0.92 and most values of precision and
recall above 0.95 (Table 3). The RF was the best performing model
with a rate of error in the classification of 2.4%.
Discriminating between ordinary reactions, i.e. transfusion-
associated dyspnoea (ATR code 17), hypotensive transfusion reac-
tion (ATR code 18), anaphylaxis (ATR code 3), acute haemolytic
transfusion reaction (ATR code 23), TACO (ATR code 8) and other
acute reactions (ATR code 1), was somewhat more challenging
(Table 4). At the best-case scenario, classification error was around
25%, mainly due to the poor predictive performance exhibited for
anaphylaxis (ATR code 3) and TACO (ATR code 8), which had values
of recall often below 0.5. Results for acute haemolytic transfusion
reaction (ATR code 23) and transfusion-associated dyspnoea (ATRcode 17) also presented limited precision and/or recall abilities.
Overall, the SVM was the best-performing model.
As shown in Table 5, the classification of the rare reactions (i.e.
those with seldom representation in the knowledge base) was
challenging even for specialised models, i.e. half of the models
achieved a kappa value between 0.5 and 0.6. The ANN and the
DT were the only models able to produce decent predictions for
viral infections (ATR code 10), TRALI (ATR code 9) and bacterial
infections (ATR code 7) in a consistent manner. Most notably, those
models were the only ones able to classify delayed haemolytic
transfusion reactions (ATR code 14) satisfactorily.
4.3. Results from the test phase
Based on the training phase results, the final hybridised classi-
fication model included a SVM model for discriminating the most
Table 3
Performance of the specialised predictive models for the prevalent ATR category: febrile non-haemolytic transfusion reactions (ATR code 15) and acute allergic reactions (ATR
code 16) by 10-fold cross-validation.
ATR code
Kappa % accuracy 15 16
DT 0.92 96.2 0.9675 0.9515 Precision/Recall
0.9744 0.9388
NB 0.93 96.62 0.9744 0.9509
0.9737 0.9521
SVM 0.94 97.36 0.9707 0.9793
0.9893 0.9441
RF 0.95 97.6 0.9728 0.9821
0.9908 0.9481
AB 0.94 97.22 0.972 0.9727
0.9858 0.9468
ANN 0.93 96.9 0.9725 0.9622
0.9801 0.9481
5NN 0.93 97 0.966 0.9777
0.9886 0.9348
Table 4
Performance of the specialised predictive models for the ordinary ATR category: transfusion-associated dyspnoea (ATR code 17), hypotensive transfusion reaction (ATR code 18),
anaphylaxis (ATR code 3), acute haemolytic transfusion reaction (ATR code 23), TACO (ATR code 8) and other acute reactions (ATR code 1) by 10-fold cross-validation.
ATR code
Kappa % accuracy 1 17 18 23 3 8
DT 0.49 62.37 0.7224 0.6058 0.7246 0.3684 0.2258 0.4844 Precision/Recall
0.7808 0.7412 0.641 0.3415 0.2258 0.2793
NB 0.61 71.06 0.8148 0.6412 0.8267 0.7632 0.3714 0.5631
0.8462 0.6412 0.7949 0.7073 0.4194 0.5225
SVM 0.66 74.96 0.8235 0.6384 0.7753 0.9583 0.8333 0.7105
0.8615 0.8412 0.8846 0.561 0.1613 0.4865
RF 0.62 72.06 0.7942 0.6183 0.7416 0.7826 0.5385 0.7917
0.8462 0.8765 0.8462 0.439 0.2258 0.3423
AB 0.55 67.44 0.7196 0.6078 0.7727 0.8571 0.4444 0.5895
0.8192 0.7294 0.6538 0.439 0.129 0.5045
ANN 0.61 70.91 0.8231 0.6188 0.7831 0.7576 0.4706 0.5641
0.8231 0.6588 0.8333 0.6098 0.2581 0.5946
5NN 0.52 65.56 0.6901 0.5922 0.7436 1 0.6667 0.5714
0.8308 0.7176 0.7436 0.1707 0.0645 0.4324
Table 5
Performance of the specialised predictive models for the rare ATR category: viral infections (ATR code 10), delayed haemolytic transfusion reactions (ATR code 14), TRALI (ATR
code 9) and bacterial infections (ATR code 7) by leave-one-out validation.
ATR code
Kappa % accuracy 10 14 7 9
DT 0.71 78.26 1 0.8 0.5714 0.8571 Precision/Recall
0.8 1 0.8 0.6667
NB 0.58 69.57 0.5 1 0.6667 0.875
0.8 0.25 0.8 0.7778
SVM 0.58 69.57 0.5 0 0.8 0.8889
0.8 0 0.8 0.8889
RF 0.57 69.57 0.4444 0 1 0.9
0.8 0 0.6 1
AB 0.57 69.57 0.6667 0.5 0.6667 0.8
0.8 0.5 0.4 0.8889
ANN 0.76 82.61 1 0.8 0.6667 0.875
0.8 1 0.8 0.7778
5NN 0.52 65.22 0.5 0.3333 0.75 0.875
0.8 0.25 0.6 0.7778
764 A. Ramoa et al. / Neurocomputing 423 (2021) 756–767probable type of reaction, a RF model for classifying prevalent reac-
tions (i.e. febrile non-haemolytic reactions and allergic reactions),
an ANN model specialised in rare reactions (i.e. viral infections,
TRALI, bacterial infections, and delayed haemolytic transfusion
reactions), and a SVM for classifying ordinary reactions (i.e. all
other ATRs).
The predictive capability of this hybridised classification model
was further demonstrated in the test phase, as the data in the test
set were completely independent of the training set and not used
for model building. From the previously unseen 959 examples,the model was able to accurately predict the reaction type of 823
notifications. The 136 false predictions are described in Table 6
and Fig. 6. Most errors related to the false prediction of febrile
non-haemolytic transfusion reactions (ATR code 15) and
transfusion-associated dyspnoea (ATR code 17).
The analysis of these misclassifications confirmed our suspi-
cions regarding the need to implement new notification
features and reorganise the signs, symptoms, diagnostic test
results, medications and other features currently in use. In more
detail:
Table 6
Performance of the hybridised classification model over the test set.
Final prediction
1 3 7 8 9 10 14 15 16 17 18 23
True class 1 0 0 2 0 0 0 24 7 6 3 1
3 1 0 1 0 0 0 1 3 3 0 0
7 0 0 0 0 0 0 1 0 0 0 0
8 3 0 0 0 0 0 3 0 14 0 0
9 0 0 0 0 0 0 0 0 3 0 0
10 1 0 0 0 0 0 0 0 0 0 0
14 1 0 0 0 0 0 0 0 0 0 0
15 5 0 0 0 0 0 0 5 3 2 0
16 1 0 0 0 0 0 0 3 6 2 0
17 1 0 0 5 0 0 0 6 5 1 0
18 0 0 0 0 0 0 0 0 2 1 0
23 1 0 0 0 0 0 0 7 0 1 1
A. Ramoa et al. / Neurocomputing 423 (2021) 756–767 765	 Anaphylactic reactions (ATR code 3) were misclassified 9 times:
o In 3 of these notifications, the severity of the reaction was
classified as ‘‘Non severe”, which is not correct.
o Other 3 of these notifications were classified as acute allergic
reactions (ATR code 16), whose feature characterisation is
currently very similar.
	 TACO (ATR code 8) was misclassified 20 times and, most nota-
bly, 14 of these cases were misclassified as TAD (ATR code 17).
	 TRALI (ATR code 9) was misclassified 3 times, all of them as TAD
(ATR code 17), which is in line with the previously explained
difficulty to distinguish between TACO (ATR code 8), TRALI
(ATR code 9) and TAD (ATR code 17) reactions [50–53].
	 Febrile non-haemolytic transfusion reactions (ATR code 15)
were misclassified 15 times:
o In 9 of these cases, the sign fever was not selected, which is
not correct.
o In other 5 cases, other symptoms, such as rash, were also
selected which led the predictive model to consider them
more similar to acute allergic reactions (ATR code 16).
	 Acute allergic reactions (ATR code 16) was misclassified 12
times:
o 6 of these cases were classified as transfusion-associated
dyspnoea (ATR code 17), because the symptom dyspnoea
was present, which is the most important symptom of this
reaction type.
o In the remaining 6 cases, classified as other acute reactions
(ATR code 1), febrile non haemolytic transfusion reactions
(ATR code 15), and hypotensive transfusion reactions (ATR
code 18), no symptom specific to allergic reactions (ATR code
16) was present.Fig. 6. Graphical representation of the c	 Hypotensive transfusion reactions (ATR code 18) were misclas-
sified 3 times because the cases were over-characterized, i.e.
more symptoms and signs were selected.
The study of these cases is essential to define strategies to
decrease misclassifications. In this context, the implementation
of reaction-targeted rules that hamper notifications to be submit-
ted when key symptoms are not selected by the notifier, as well
as a ponderation system that prevents overvaluation of some
symptoms in specific reactions (i.e. a symptom when identified
together with others, should be less valued than when it is identi-
fied alone) seem to be relevant issues to be addressed.5. Conclusions and further work
This paper introduced a hybrid decision support system, based
on machine learning inference and rule-based reasoning, to assist
in the categorisation of adverse reactions in blood transfusion
recipients. The system indicates the most probable reaction(s)
according to the observed signs and symptoms and the knowledge
acquired from prior, validated notifications. The hospital notifier
may decide to accept the predicted type or to propose another
one, i.e. based on his experience or additional observations. Notifi-
cation categorisation is automatically validated against the expert
decision rules defined in accordance with European laws. The hos-
pital notifiers and, ultimately, the Haemovigilance experts manu-
ally resolve the non-compliances.
The experimental testbed carried out for 10-year records of the
Portuguese National Haemovigilance System demonstrated that
the implementation of a decision support system such as the oneonfusion matrix shown in Table 6.
766 A. Ramoa et al. / Neurocomputing 423 (2021) 756–767proposed here is of practical use to the operation of national Hae-
movigilance systems. Most notably, data introduction and valida-
tion processes can benefit from some degree of intelligent,
expert-guided automation that may reduce the manual workload
of experts significantly. Moreover, these experiments brought to
light some deficiencies in current reaction characterisation, which
will certainly promote additional monitoring during the notifica-
tion and validation processes.
The implementation of this system is expected to improve the
quality of future adverse reaction notifications and, most notably,
minimise the manual intervention of Haemovigilance experts in
the process. In particular, the notifier will be directed to either
characterise the adverse reaction in such a way that all ‘‘manda-
tory” features (i.e. those that experts deemed as necessary to
ensure the occurrence of such type of reaction) are checked, or con-
sider other possible adverse reactions if such features do not apply.
Therefore, this system can be also seen as a training tool for new
(and current) hospital notifiers.
With an expected notification rate of 400 adverse reactions per
year in Portugal, it will soon be possible to extract a new dataset
and use these (semi-) automatically revised notifications to further
improve the predictive models. Another future line of work will be
the study of current data on the adverse reaction in donors, which
surpassed 10,000 records in the last 10 years. While these adverse
reactions have different feature profiles, an approach similar to the
proposed here holds the potential to improve the quality of that
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